Adding the monoclonal antibody drug trastuzumab — already used to treat
certain breast cancers — to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their
tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a
small phase II trial of the regimen, testing its safety and value.
By giving a single
small dose of
certain chemicals (aromatic polycyclic hydrocarbons) to selected strains of female rats he found he could produce, within a few weeks, malignant mammary
tumors — many of which were hormone dependent — in 100 percent of the treated animals.